1056881-04-9 Usage
Description
25-Bromo-2,5,8,11,14,17,20,23-octaoxapentacosane, also known as m-PEG8-bromide, is a PEG linker containing a bromide group. The bromide (Br) acts as an excellent leaving group for nucleophilic substitution reactions, while the hydrophilic PEG spacer enhances solubility in aqueous media. This unique structure makes it a versatile compound with potential applications in various industries.
Uses
Used in Pharmaceutical Industry:
25-Bromo-2,5,8,11,14,17,20,23-octaoxapentacosane is used as a building block for the synthesis of various pharmaceutical compounds. The bromide group facilitates nucleophilic substitution reactions, allowing for the attachment of different functional groups to create a wide range of molecules with specific therapeutic properties.
Used in Drug Delivery Systems:
In the field of drug delivery, 25-Bromo-2,5,8,11,14,17,20,23-octaoxapentacosane is used as a component in the design of targeted drug delivery systems. The hydrophilic PEG spacer improves the solubility and bioavailability of the drug, while the bromide group can be used to attach targeting ligands or other functional groups to enhance the specificity and efficacy of the drug delivery system.
Used in Chemical Synthesis:
25-Bromo-2,5,8,11,14,17,20,23-octaoxapentacosane is used as an intermediate in the synthesis of various organic compounds. The bromide group's reactivity in nucleophilic substitution reactions makes it a valuable starting material for the preparation of a wide range of molecules with different functional groups and applications.
Used in Material Science:
In material science, 25-Bromo-2,5,8,11,14,17,20,23-octaoxapentacosane can be used as a component in the development of novel materials with specific properties. The hydrophilic PEG spacer can improve the solubility and compatibility of the material with aqueous environments, while the bromide group can be used to introduce additional functional groups or cross-linking agents to tailor the material's properties.
Overall, 25-Bromo-2,5,8,11,14,17,20,23-octaoxapentacosane is a versatile compound with a wide range of potential applications across various industries, including pharmaceuticals, drug delivery, chemical synthesis, and material science. Its unique structure, featuring a reactive bromide group and a hydrophilic PEG spacer, makes it a valuable building block for the development of new compounds and materials with specific properties and functions.
Check Digit Verification of cas no
The CAS Registry Mumber 1056881-04-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,6,8,8 and 1 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1056881-04:
(9*1)+(8*0)+(7*5)+(6*6)+(5*8)+(4*8)+(3*1)+(2*0)+(1*4)=159
159 % 10 = 9
So 1056881-04-9 is a valid CAS Registry Number.
1056881-04-9Relevant articles and documents
Complex compound
-
Paragraph 0042; 0044, (2016/10/10)
PROBLEM TO BE SOLVED: To provide a new complex compound that can be used as a catalyst for an organic synthesis reaction and in particular a surfactant type catalyst having both functions of catalytic ability and surface active ability. SOLUTION: A complex compound comprises a nitrogen-containing heterocyclic carbene ligand represented by formula (A) and including at least one metal atom selected from palladium, silver, rhodium, iridium, and ruthenium as a central metal. (R1 represents a divalent hydrocarbon group that has 2-20 carbon atoms and may include at least one atom selected from N, O, S and halogen atoms; R2 represents a hydrocarbon group having 6-70 carbon atoms and including a polyoxyalkylene group and/or a polyglyceryl group having a polymerization number of 2-20 or a hydrocarbon group having 2-20 carbon atoms and including at least one ionic functional group selected from a sulfonic acid group, a carboxyl group, an ammonium group, or their salts; and R3 represents a hydrocarbon group having 2-20 carbon atoms) SELECTED DRAWING: None COPYRIGHT: (C)2016,JPO&INPIT
